Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Neuren Pharmaceuticals Limited ( (AU:NEU) ) has issued an announcement.
Neuren Pharmaceuticals reported strong financial momentum driven by the continued uptake of DAYBUE in the U.S., as Acadia recorded 2025 net sales of US$391 million, up 12% year-on-year, and Q4 sales of US$110 million, a quarterly record supported by rising patient numbers and broader prescribing among community physicians. Neuren’s 2025 royalty income from DAYBUE rose 15% to A$65 million, and based on Acadia’s 2026 sales guidance of US$460–490 million, the company expects royalties of A$70–77 million while its partner advances European regulatory re-examination and a Phase 3 trial in Japan, underscoring growing global prospects for trofinetide and a strengthening cash-generative base for Neuren.
Neuren Pharmaceuticals reported strong financial momentum driven by the continued uptake of DAYBUE in the U.S., as Acadia recorded 2025 net sales of US$391 million, up 12% year-on-year, and Q4 sales of US$110 million, a quarterly record supported by rising patient numbers and broader prescribing among community physicians. Neuren’s 2025 royalty income from DAYBUE rose 15% to A$65 million, and based on Acadia’s 2026 sales guidance of US$460–490 million, the company expects royalties of A$70–77 million while its partner advances European regulatory re-examination and a Phase 3 trial in Japan, underscoring growing global prospects for trofinetide and a strengthening cash-generative base for Neuren.
The most recent analyst rating on (AU:NEU) stock is a Buy with a A$27.00 price target. To see the full list of analyst forecasts on Neuren Pharmaceuticals Limited stock, see the AU:NEU Stock Forecast page.
More about Neuren Pharmaceuticals Limited
Neuren Pharmaceuticals is an Australian biopharmaceutical company focused on therapies for neurological disorders, including rare pediatric conditions. Its key commercial exposure comes through royalties from DAYBUE (trofinetide), marketed by U.S.-based partner Acadia Pharmaceuticals, with additional development activities targeting Europe and Japan.
Average Trading Volume: 364,836
Technical Sentiment Signal: Sell
Current Market Cap: A$1.55B
For an in-depth examination of NEU stock, go to TipRanks’ Overview page.